OIP E COM NOT THE WAY

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031

Page 1 of 5

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)
Sheet 1 of 2

a conocuon or intormation unless it displays	YANG OND CONDUITION.	
Application Number	09/920,262	1
Filing Date	August 1, 2001	ì
First Named Inventor	David M. Knight	1
Group Art Unit	Not Assigned 164	1
Examiner Name	Not Assigned Premay	kn
Attorney Docket Number	CEN-248	1

		U.S. Patent Do	ocument	U.S. PATENT DOCUMENTS	T	
Examiner	Cite		Kind Code <sup>2</sup>	Name of Patentee or Applicant	Date of Publication of Cited Document	Pages, Columns, Lines,
Initials	No.1	Number	(if known)	of Cited Document	mm-dd-yyyy	where relevant passages or relevant figures appear
		<u> </u>			1	
					1	
	L	<u> </u>			<del>-</del>	
			1 1		[	
					<del>                                     </del>	
	ļ				<del> </del>	
		<del></del>			<del> </del>	
			1			
					1	
					<del> </del>	<del></del>
		<del></del>	<del></del>		<del> </del>	
			FORE	GN PATENT DOCUMENTS		

HE DATENT DOCUMENTS

					CIGIT ATENT DOCUMENTS				
			Foreign	Patent Docum	ent	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Cite Initials No.1		Office <sup>3</sup>	Number <sup>4</sup> K	indCode <sup>6</sup>	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T <sup>6</sup>	
PM		wo	97 15327	A	US HEALTH	05-01-1997			
		wo	96 33735	Α	CELL GENESYS INC	10-31-1996			
		wo	99 37682	Α	HOFFMANN LA ROCHE	07-29-1999			
_~		wo	00 56772	Α	BASF AG	09-28-2000			

Examiner Signature	Prima	Mente	Date Considered	5	20	104	
TO A BAILTON	1-145-1 16 6			., ., .			 _

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

s Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Under the Paperwor
Substitute for form 1449A/PTO

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Page 2 \$ 5

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays	a valid OMB control number.	_
Application Number	09/920,262	]
Filing Date	August 1, 2001	i
First Named Inventor	David M. Knight	
Group Art Unit	Not Assigned 1646	ł
Examiner Name	Not Assigned Prema	Ments-
Attorney Docket Number	CEN-248	3
	1	ł

,		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner's Initials*	Cite No.1	Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
PM		NIKHIL, YWALKAR ET AL.; "Expression of interleukin-12 is increased in psoriatic skin", Journal of Investigative Dermalology, December 1998, pages 1053-1057; Vol. 111, no. 6; XP00800577; ISSN: 0022-202X, abstract	

Examiner D	M 11	Date		7	
Signature / WWW	lung		5 19 1	11/1	
Olgitatore 7 0	001	Considered	10~0	107	

and the second s

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through cilation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Discription designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

#### SUBMISSION UNDER MPEP 609 D

09/920,262 August 1, 2001 Application Number Filing Date First Named Inventor David M. Knight Not Assigned | 6 4 b Group Art Unit Examiner Name Attorney Docket Number **CEN-248** 

Page 1 of 1

U.S. PATENT DOCUMENTS											
		Pages, Columns, Lines,									
Cite No. <sup>1</sup>	of Cited Document	Kind Code <sup>2</sup> Number (if known)		where relevant passages or							
	ı										
		1 of Cited Document	Cite Name of Patentee or Applicant of Cited Document	of Cited Document							

FOREIGN PATENT DOCUMENTS Pages, Columns, Lines, where relevant passages or relevant figures Foreign Patent Document Name of Patentee or Examiner Cite Applicant of Cited Document Number<sup>4</sup> KindCode<sup>5</sup> Office<sup>3</sup> appear OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS
Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), Cite No.<sup>1</sup> title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), Examiner volume-issue number(s), publisher, city and/or country where published PCT International Search Report PCT/US01/24720 dated 07-30-2002

Examiner Signature	Ment	Date Considered	5/20	04	
			$-\tau$		

E TRADE!

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

LIS DATENT DOCUMENTS

ubstitute for form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

a collection of information unless it displays a	valid OMB control number.
Application Number	09/920,262
Filing Date	August 1, 2001
First Named Inventor	David M. Knight
Group Art Unit	1646
Examiner Name	Brema Ment-
Attomey Docket Number	CEN-248-NP

	Ī		U.S. Patent Doo	cument	·		
Examiner Initials			Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	
PM	B.4	6,300,478	B1	Trinchieri et.I	October 09, 2001		
	3-2	5,891,680		Lieschke et. al	April 06, 1999		
	83	5,811,523		Trinchieri et. al	Sept. 22, 1998	<b>♠</b>	
	34	5,648,467		Trinchieri et. al	July 15, 1997	\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\	
	35	5,457,038		Trinchieri et. al	October 10,1995	10 V	
	36	5,648,467		Trinchieri et. al	July 15,1997	CHO ON L	
	3.7	6,225,117	81	Gately et. ai	May 1, 2001	W/6 3200	
	<b>B</b> .8	5,780,597		Gately et. al	July 14, 1998	19/60	
	<b>38.9</b>	6,225,117	B1	Gately et. al	May 01, 2001	ECH ON 0 510 ECH ON 1ER 1500 2003	
	310	5,891,680		Lieschke at. al	. April 06, 1999	900	
	B-11	6,338,848	B1	Leonard et. al	January 15, 2002		
	3.12	6,495,667	B1	Bazan	Dec. 17, 2002		
	315	5,547,852		Seller et. al	August 20, 1996		
1	B-14	6,086,876		Karp et. al	July 11, 2000		

Examiner Cite Initials No.1		Foreign	Patent Docume	ent	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
		Office <sup>3</sup>	Number <sup>4</sup> K	indCode⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	T°
PM .	3-15	wo	01/19373	A2	BASF AG.	03/22/2001		
	316	wo	92/05256	A1	GENETICS INSTITUTE, INC.	04/02/1992		
	3/7	wo	90/05147	A1	GENETICS INSTITUTE, INC.	05/17/1990		
	B-18	wo	99/37682	A2	F. HOFFMANN- LA ROCHE AG	04/29/1999		
\	319	wo	00/56772	A1	BASF AG	09/28/2000		
	330	EP	804581	B1	CORIXA CORP.	09/20/2001		
	321	EP	433827	B1	F. HOFFMANN LA ROCHE AG	03/04/1998		
4	Baa	EP	790255	A2	F. HOFFMANN LA ROCHE AG	08/20/1997		

Examiner Men Signature Considered EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if

and not considered. Include copy of this form with next communication to applicant.

possible. e Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

a collection of information unless it displays	a valid OMB control number.
Application Number	09/920,262
Filing Date	August 1, 2001
First Named Inventor	David M. Knight
Group Art Unit	1666
Examiner Name	CEN-248-NP
Attomey Docket Number	CÉN-248-NP

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Include name of the author (in CAPITOL LETTERS), title of the article (when appropriate), title			
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T <sup>2</sup>
Initials*	No.1	publisher, city and/or country where published	
		A. U. GUBLER et. al. (COEXPRESSION OF TWO DISTINCT GENES IS REQUIRED TO GENERATE SECRETED	
PM 30.23		BIOACTIVE CYTOTOXIC LYMPHOCYTE MATURATION FACTOR) Proc. Natl. acad. Sci. USA. Vol. 88, pp 4143-4147-	
		(May 1991) Immunology.	
1		A. U. GUBLER et. at (CLONIC AND EXPRESSION OF CYTOTOXIC LYMPHOCYTE MATURATION FACTOR (CLMF) A	
1 1	3-24	HETERODIMERIC LYMPHOKINE THAT POTENTIATES NR. LAK NA D T-CELL REPONSES) Abstracts Journal of celluar Biochemistry Supplement 15 F: 70 (1991)	
<del>1</del> 7		BIOGRAPHICATION OF CYTOTOXIC	
1 1	ار م	LYMPHOCYTE MATURATION FACTOR FROM HUMAN B-LYMPHOBLASTOID CELLS) (JUNE 11, 1990) F. HOFFMANN	
	B-21	LA ROCHE INC. NUTLEY NJ USA. Proc. National Acad. Sci. USA (Vol. 87 pp 6808-6812- Sept 1990- Immunology)	
		M. GATELY et. al. (REGULATION OF HUMAN LYMPHOCYTE PROLIFERATION BY A HETERODIMERIC CYTOKINE IL-	
1 1	3.26	12 (CYTOTOXIC LYMPHOCYTE MATURATION FACTOR) Vol.147- 874-882 No. 3. (August 1, 1991).(The Journal of	
		Immunology)  R. CHIZZONITE et. al. (IL-12 MONOCLONAL ANTIBODIES SPECIFIC FOR THE 40-KdA SUBUNIT BLOCK RECEPTOR	
1 12	1-17	BINDING AND BIOLOGIC ACTIVITY ON ACTIVATED HUMAN LYMPHOBLASTS, Vol. 147,1548-1556-No. 5	'
	-41	(Sep1,1991) The Journal of Immunology,	
	-28	SUSAN H. CHAN et. al. (INTRODUCTION OF INTERFERON PRODUCTION BY NATURAL KILLER CELL STIMULATORY	
		FACTOR CHARACTERIZATION OF THE RESPONDER CELLS AND SYNERGY WITH OTHER INDUCERS) (THE	
	0 7	ROCKEFELLER UNIVERSITY PRESS)- 0022-1007/91/04/0869/-Vol. 173 April 1991-pp869-879  ANNALISA D'ANDREA et. al. (PRODUCTION OF NATURAL KILLER CELL STIMULATORY FACTOR (INTERLEUKIN 12)	
ا جا	200	BY PERIPHERAL BLOOD MONONOUCLEAR CELL) J. Exp. Med. The Rockefeller university press- 0022-1007/92/11/1387	
13	3-29	Vol. 176 November 1992 pp. 1387-1398	
4	20	MARKUS F. NEURATH et al. (ANTIBODIES TO INTERLEUKIN 12 ABROGATE ESTABLISHED EXPERIMENTAL	
	- 30	COLITIS IN MICE) The Journal of Experimental Medicine – Vol. 182- Nov. 1995- pp.1281-1290	
B	-31	R.W. CARTER. et. al. (PRODUCTION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES TO HUMAN	
<del>-1-2</del> 1	•	INTERLEUKIN -12) HYBRIIDONA 16: 363-369 (1997)  NICOLAS M. VALIANTE et. al. ( ROLE OF THE PRODUCTION OF NATURAL KILLER CELL STIMULATORY FACTOR	
I R	.32	(NKSF/L-12) IN THE ABILITY OF B CELL LINES TO STIMULATE T AND NK CELL PROLIFERATION). Cellunar	
1 2 1	, 20	Immunology 145, 187-198-(1992)	
		RAINER DUCHMANN et. al. (TOLÉRANCE TOWARDS RÉSIDENT INTESTINAL FLORA IN MICE IS ABROGATED IN	
1 . 7	5 - 31	EXPERIMENTAL COLITIS AND RESTORES BY TREATMENT WITH INTELUKIN-1 OR ANTIBODIES TO INTERLEUKIN-1	
-+=		12) Eur. J. Immunol 196-26: 394-938 MICHIKO KOBAYASHI et. al. I ( IDENTIFICATION AND PURIFICATION OF NATURAL KILLER CELL STIMULATORY	
17	200	MICHINO ROBATASHI EL. BI. I IDENTIFICATION AND FURIFICATION OF INATURAL RICLER CELL STIMULATION FACTOR (NKSF) A CYTOKINE WITH MULTIPLE BIOLOGIC EFECTS ON HUMAN LYMPHOCYTES) J. Exp. Med. The	
- 1 ,44	7.34	Rockefeller university Press- Vol. 170-(Sept. 1989) pp. 827-845	
1.7	2/-	SYLVIE TREMBLEAU et. al. (THE ROLE OF IL-12 IN THE INDUCTION OF ORGAN-SPECIFIC AUTOIMMUNE	
VO1	בכי	DISEASES)	

Examiner	Α	,	Date			<i>i</i> .	
Signature	l Prema M	1M.	Considered		اللا	100	
Signature	1700000	~ ч			0	- 7	 
			 	$-\tau$		/	 

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and

Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.